Expansion of tumor-reactive T cells from patients with pancreatic cancer

Journal of Immunotherapy

Volumn 39, Issue 2, 2016, Pages 81-89

  Meng, Qingda ^a   Liu, Zhenjiang ^a   Rangelova, Elena ^b   Poiret, Thomas ^a   Ambati, Aditya ^a   Rane, Lalit ^a   Xie, Shanshan ^c   Verbeke, Caroline ^c   Dodoo, Ernest ^c   Del Chiaro, Marco ^b   Löhr, Matthias ^b   Segersvärd, Ralf ^b   Maeurer, Markus J ^a,c  

^a Department of Laboratory Medicine   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adoptive transfer therapy; Pancreatic cancer; TILs; Tumor antigen

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; MESOTHELIN; NY ESO 1 ANTIGEN; OKT 3; SURVIVIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL MEDIATED CYTOTOXICITY; CHROMIUM RELEASE ASSAY; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE CULTURE; MALE; MEMORY T LYMPHOCYTE; MIDDLE AGED; PANCREAS ADENOCARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; ADENOCARCINOMA; ADOPTIVE IMMUNOTHERAPY; CELL CULTURE; CELL PROLIFERATION; CYTOTOXICITY; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PANCREATIC NEOPLASMS; PROCEDURES;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL;

EID: 84957945015     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000111     Document Type: Article

References (73)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Matano E, Tagliaferri P, Libroia A, et al. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. Br J Cancer. 2000;82:1772-1775.
3. Fridman WH, Galon J, Pages F, et al. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res. 2011;71:5601-5605.
4. Galon J, Pages F, Marincola FM, et al. Cancer classification using the immunoscore: a worldwide task force. J Transl Med. 2012;10:205.
5. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362: 1605-1617.
6. Protti MP, De Monte L. Immune infiltrates as predictive markers of survival in pancreatic cancer patients. Front Physiol. 2013;4:210.
7. Erkan M, Hausmann S, Michalski CW, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9:454-467.
8. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4:583-594.
9. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309-322.
10. Ademmer K, Ebert M, Muller-Ostermeyer F, et al. Effector T lymphocyte subsets in human pancreatic cancer: detection of CD8+CD18+ cells and CD8+CD103+ cells by multiepitope imaging. Clin Exp Immunol. 1998;112:21-26.
11. Ryschich E, Notzel T, Hinz U, et al. Control of T-cellmediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res. 2005;11(pt 1):498-504.
12. von Bernstorff W, Voss M, Freichel S, et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res. 2001;7(suppl):925s-932ss.
13. Fukunaga A, Miyamoto M, Cho Y, et al. CD8(+) tumorinfiltrating lymphocytes together with CD4(+) tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28: E26-E31.
14. Ino Y, Yamazaki-Itoh R, Shimada K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108:914-923.
15. De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011;208:469-478.
16. Hartmann N, Giese NA, Giese T, et al. Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer. Clin Cancer Res. 2014;20:3422-3433.
17. Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67:9518-9527.
18. Zoglmeier C, Bauer H, Norenberg D, et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res. 2011;17:1765-1775.
19. Bellone G, Turletti A, Artusio E, et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol. 1999;155:537-547.
20. Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60: 1419-1430.
21. Tassi E, Gavazzi F, Albarello L, et al. Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. J Immunol. 2008;181:6595-6603.
22. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538-18543.
23. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203-213.
24. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964.
25. Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27:5944-5951.
26. Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008;113:1387-1395.
27. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62-68.
28. Magalhaes I, Vudattu NK, Jager E, et al. Tumor antigenspecific T-cells are present in the CD8alphaalpha+ T-cell effector-memory pool. J Immunother. 2008;31:840-848.
29. Ahmed RK, Poiret T, Ambati A, et al. TCR+CD4-CD8-T cells in antigen-specific MHC class I-restricted T-cell responses after allogeneic hematopoietic stem cell transplantation. J Immunother. 2014;37:416-425.
30. Tran KQ, Zhou J, Durflinger KH, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008;31:742-751.
31. Dudley ME, Gross CA, Langhan MM, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010;16:6122-6131.
32. Itzhaki O, Hovav E, Ziporen Y, et al. Establishment and largescale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother. 2011;34:212-220.
33. Besser MJ, Shapira-Frommer R, Treves AJ, et al. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J Immunother. 2009;32:415-423.
34. Besser MJ, Shapira-Frommer R, Treves AJ, et al. Clinical responses in a phase II study using adoptive transfer of shortterm cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16:2646-2655.
35. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299-308.
36. Ku CC, Murakami M, Sakamoto A, et al. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science. 2000;288:675-678.
37. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood. 2006;107:2409-2414.
38. Cesana GC, DeRaffele G, Cohen S, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006;24:1169-1177.
39. Rosenberg SA. Overcoming obstacles to the effective immunotherapy of human cancer. Proc Natl Acad Sci U S A. 2008;105:12643-12644.
40. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294-305.
41. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4:225-234.
42. Chapuis AG, Thompson JA, Margolin KA, et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A. 2012;109:4592-4597.
43. Butler MO, Friedlander P, Milstein MI, et al. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med. 2011;3:80ra34.
44. Gartner JJ, Parker SC, Prickett TD, et al. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A. 2013; 110:13481-13486.
45. Yamaguchi N, Hattori K, Oh-eda M, et al. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994;269: 805-808.
46. Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem. 1995;270:21984-21990.
47. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10(pt 1):3937-3942.
48. Hassan R, Laszik ZG, Lerner M, et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005;124:838-845.
49. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396: 580-584.
50. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
51. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113:1076-1081.
52. Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001;92:271-278.
53. Schmidt SM, Schag K, Muller MR, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood. 2003;102:571-576.
54. Islam A, Kageyama H, Takada N, et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000;19:617-623.
55. Swana HS, Grossman D, Anthony JN, et al. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999;341:452-453.
56. Widenmeyer M, Griesemann H, Stevanovic S, et al. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer. 2012;131:140-149.
57. Jager E, Nagata Y, Gnjatic S, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A. 2000;97: 4760-4765.
58. Gure AO, Tureci O, Sahin U, et al. SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer. 1997;72:965-971.
59. Jager D, Unkelbach M, Frei C, et al. Identification of tumorrestricted antigens NY-BR-1, SCP-1, and a new cancer/testislike antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. Cancer Immun. 2002;2:5.
60. Kubuschok B, Xie X, Jesnowski R, et al. Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. Int J Cancer. 2004; 109:568-575.
61. Liu YJ, Soumelis V, Watanabe N, et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol. 2007;25:193-219.
62. Formentini A, Prokopchuk O, Strater J, et al. Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases. Int J Colorectal Dis. 2009;24:57-67.
63. Kornmann M, Kleeff J, Debinski W, et al. Pancreatic cancer cells express interleukin-13 and-4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and-4. Anticancer Res. 1999;19(1A):125-131.
64. Whatcott C, Han H, Posner RG, et al. Tumor-stromal interactions in pancreatic cancer. Crit Rev Oncog. 2013;18: 135-151.
65. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612-1616.
66. Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer cell. 2014;25:735-747.
67. Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with clinical response in dendritic cellbased immunotherapy for malignant melanoma. Clin Cancer Res. 2003;9:998-1008.
68. Carrasco J, Van Pel A, Neyns B, et al. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine antitumor cells. J Immunol. 2008;180:3585-3593.
69. Kaneko T, Goto S, Kato A, et al. Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer. Anticancer Res. 2005;25(6A):3709-3714.
70. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889-897.
71. Uggeri F, Caprotti R, De Grate L, et al. Short-term preoperative IL-2 immunotherapy in operable pancreatic cancer: a randomized study. Hepatogastroenterology. 2009;56: 861-865.
72. Degrate L, Nobili C, Franciosi C, et al. Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients. Langenbecks Arch Surg. 2009;394:115-121.
73. Ferradini L, Mackensen A, Genevee C, et al. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest. 1993;91:1183-1190.